PTC Therapeutics, Inc. (PTCT)
PTC Therapeutics (PTCT) Reports Q1 Loss, Tops Revenue Estimates
PTC Therapeutics (PTCT) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to earnings of $10.04 per share a year ago.
Exploring Analyst Estimates for PTC Therapeutics (PTCT) Q1 Earnings, Beyond Revenue and EPS
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for PTC Therapeutics (PTCT), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2026.
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PTC Therapeutics, Inc. (PTCT) Discusses 24-Month Interim Results of PIVOT-HD Long-Term Extension Study of Votoplam in Huntington's Disease Transcript
PTC Therapeutics, Inc. (PTCT) Discusses 24-Month Interim Results of PIVOT-HD Long-Term Extension Study of Votoplam in Huntington's Disease Transcript
Abacus FCF Advisors LLC Makes New $5.76 Million Investment in PTC Therapeutics, Inc. $PTCT
Abacus FCF Advisors LLC bought a new stake in PTC Therapeutics, Inc. (NASDAQ: PTCT) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 75,757 shares of the biopharmaceutical company's stock, valued at approximately $5,755,000. Abacus FCF Advisors LLC owned about 0.09% of
Cinctive Capital Management LP Takes Position in PTC Therapeutics, Inc. $PTCT
Cinctive Capital Management LP purchased a new position in PTC Therapeutics, Inc. (NASDAQ: PTCT) in the undefined quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 95,308 shares of the biopharmaceutical company's stock, valued at approximately $5,849,000. Cinctive Capital Management LP owned about 0.12% of PTC
PTC Therapeutics, Inc. (PTCT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
PTC Therapeutics, Inc. (PTCT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
PTC Therapeutics, Inc. (PTCT) Presents at Leerink Global Healthcare Conference 2026 Transcript
PTC Therapeutics, Inc. (PTCT) Presents at Leerink Global Healthcare Conference 2026 Transcript
PTC Therapeutics, Inc. (PTCT) Q4 2025 Earnings Call Transcript
PTC Therapeutics, Inc. (PTCT) Q4 2025 Earnings Call Transcript
PTC Therapeutics (PTCT) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for PTC Therapeutics (PTCT) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
PTC Therapeutics (PTCT) Reports Q4 Loss, Misses Revenue Estimates
PTC Therapeutics (PTCT) came out with a quarterly loss of $1.67 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to a loss of $0.24 per share a year ago.
Ahead of PTC Therapeutics (PTCT) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Besides Wall Street's top-and-bottom-line estimates for PTC Therapeutics (PTCT), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2025.
